Heidelberg Pharma to Present New Clinical Data on Its ATAC Candidates at the ASH Annual Meeting 2026
LADENBURG, GERMANY - November 4, 2026 ( NEWMEDIAWIRE ) - Heidelberg Pharma AG (FSE: HPHA), a clinical stage company developing innovative Antibody Drug Conjugates (ADCs), will present new data from its Phase I/IIa clinical study with its lead Amanitin-based ADC candidate, pamlectabart tismanitin (HDP-101), in an oral presentation, as well as data from its second clinical candidate, HDP-102, during the poster abstract session of the 68th Annual Meeting of the American Society of Hematology (ASH) , being held in New Orleans, USA, from 12 to 15 December 2026. Details of the oral presentation (HDP-101): Presentation title: First-in-human phase 1/2a study of pamlectabart tismanitin (HDP-101), an amanitin-based BCMA-targeting antibody-drug conjugate (ADC): Recommended phase 2 dose (RP2D) selection and preliminary antitumor activity in relapsed/refractory multiple myeloma (RRMM) Presenter: Professor Marc-Steffen Raab, MD Publication number: 270 Session: 654. Multiple Myeloma: Pharmacologic Therapies: Novel Approaches in Relapsed Myeloma: Immunotherapies and Small Molecules Session time: Saturday, 12 December 2026, 02:00 - 03:30 pm (CDT) Presentation: Saturday, 12 December 2026, 03:15 – 03
Plan Gratis · Plus 29 CA$ o Pro 99 CA$/mes
